anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to unique traditional Chinese medicine quick-acting traumatic wine. A main medicine in a formula is a traditional Chinese medicinal material of zhuangtianlazhu which is a wild plant growing in a high mountain region in Guangdong province. The medicine blooms before or after the ninth of September on the lunar calendar and is also picked, the color is in bright red, the shape is similar to a candle, and the medicine also grows out on the ground, so that the medicine is named as the zhuangtianlazhu. Medicated wine prepared by using the formula of the medicine has a quick and unique treatment effect to traumatic injury and internal injury and can be used for quickly eliminating the blood stasis and alleviating pain. By clinical practice for many years, any adverse reaction does not occur yet. After the treatment effects of other medicines used by many people are not good, an obvious effect is obtained by replacing the medicines through the medicated wine for use.
Mechanically ventilated and sedated adult patients not infected with COVID-19 infection. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
PURPOSE: A multi-compartment micro filled facial cooling pack is provided to fill coolness or warmness maintaining filter in multi-compartments and to be portable. CONSTITUTION: A multi-compartment micro filled facial cooling pack(1) is filled with respective material. Both sides of a material filling part(2) are stitched. The width and the length of the material filling part are respectively less than 5cm. The height of the material filling part is less than 2cm. A material filling the material filling part includes a phase shift material, a gel type liquid material, and a mixed material of gel type powder and a solution.
Patients randomized to arm A undergo bilateral lymph node dissection in the pelvic area as part of prostatectomy. At least 10 lymph nodes must be removed.
Data were collected at Edirne Sultan 1. Murat State Hospital Pediatrics Clinic between September 2023 and January 2024. Children aged 3-6 were included in the study. In the research, the sample was divided into three groups. 99 children participated in the study, 33 children in each group. Using the randomization program, it was determined which sample group the children would be included in.

In the study, reading fairy tales and coloring were used as distraction methods for the experimental group. Inhaler medication was administered via mask to the control group without any application. The implementation period of the research lasted an average of four months. Necessary ethical permissions were obtained before the research. In the study, the Child Fear Scale was used to measure the level of fear, the PedsQL Health Care Satisfaction Scale was used to measure parental satisfaction, and the Children's Emotional Indicators Scale was used to measure emotional indicators. Explanatory information about the application was given to the children and their parents by the researcher, and they were voluntarily informed and signed a consent form. Research data were collected by the researcher by meeting children and parents face to face.
This is a prospective, single-arm, post-market clinical investigation to verify clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion app with TBL Backend, referred to as Actiste diabetes management system (ADMS) when used as intended by subjects diagnosed with Diabetes Mellitus Type 1 or Type 2 (T1DM or T2DM). In total, 70 subjects diagnosed with T1DM or T2DM (35 subjects per type) using Glargine U100 basal insulin with or without oral antidiabetic drugs/bolus insulin regimen will be enrolled at 1 site in the UK. Each subject will be evaluated during a period of 6 months. Eight (8) visits are planned for each subject during the clinical investigation, including 3 visits to the study clinic and 5 visits conducted as telephone calls. During the visits, evaluations will be performed to assess blood glucose levels, adherence to the treatment plan, quality of life and treatment satisfaction. Data on blood glucose values, insulin injections and diabetesrelated data from the Companion app and TBL Backend will be shared by the subject.Each participant will be provided with the ADMS, including Actiste 1.0, and the Companion app for their smartphone with the TBL Backend. No comparator will be used.
A pharmaceutical composition for the treatment of yeast and fungal infections is provided. The composition may include a micronized poloxamer composition as excipient and itraconazole as active pharmaceutical ingredient (API). The micronized poloxamer composition may include a combination of poloxamer 188 and poloxamer 407. Additionally, micronized poloxamer-based composition, used as a surfactant, may help to break out or disrupt the membrane of microorganisms' cells within biofilm, thus allowing APIs, such as itraconazole, to improve their action and effectiveness against fungus and yeast infections. Additionally, poloxamer-based composition may be delivered to the infected site by different administration routes, such as orally, topically, via nasal, lung inhalation, and transdermal delivery. Due to the synergistic effect of poloxamer-based composition, itraconazole may have improved solubility, and dispersibility, thus decreasing side effects and time of treatment.
In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may then be transported to the intra-ocular region of the patient, allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness. Data assimilation methods are also disclosed, focusing on enhancing assessment of choriocapillaris and choroidal blood flow to increase sensitivity of OCT-A monitoring. The disclosed methods can be used for treatment and clinical study plans of patients with adult onset macular degeneration and related conditions. Methods of treating various stages of diabetic retinopathy are also described.
The study was carried out in Wuhan City, China at a general public university hospital with 62 clinical departments, 99 surgical rooms, and 38 beds in the PACU. The total number of operations performed in this hospital is more than 90,000/year. The study was approved by the hospital ethics committee and was deemed that written patient consent was not required. The adverse events, including RAP, in all patients in the PACU were recorded on a standardized form in a database by pre-trained qualified nurses and/or anesthesiologists at the time of care from January 1, 2017 to December 31, 2019.

Data, including patient demographic and surgical and anesthesia parameters, were obtained from the anesthesia information system. Adverse events management and duration of PACU stay were also documented. For three years, all collected data were filed in a computer every day and were summarized and analyzed every month. Data, such as demographics, airway, oxygen saturation, consciousness, treatment, vital signs, and fast-track criteria scores, were recorded for all patients in the PACU. The first part contained preoperative and intraoperative data, which were entered into the database by the anesthesiologists involved in the patients' intraoperative care from the time of PACU admission. The second part were recorded by nurse and comprised postoperative data from the PACU to the ward or ICU. The third part were recorded by the surgeons and/ or surgical nurses and comprised postoperative data. The criteria for tracheal extubation in the operating room(OR) and the timing of transfer to the PACU were the responsibility of the anesthesiologist.
Bioavailability studies on the topical administration of 1 gram of Metronidazole Topical Gel (7.5 mg of metronidazole) to the face of 10 rosacea patients showed a maximum serum concentration of 66 nanograms per milliliter in one patient. This concentration is approximately 100 times less than concentrations afforded by a single 250 mg oral tablet. The serum metronidazole concentrations were below the detectable limits of the assay at the majority of time points in all patients. Three of the patients had no detectable serum concentrations of metronidazole at any time point. The mean dose of gel applied during clinical studies was 600 mg which represents 4.5 mg of metronidazole per application. Therefore, under normal usage levels, the formulation affords minimal serum concentrations of metronidazole. The mechanisms by which Metronidazole Topical Gel acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.
The invention provides a plant-source sterilization and antiviral agent and a preparation method thereof, which belongs to the biotechnology field. The sterilization and antiviral agent is pure vegetable and pure natural and comprises gentrin knotweed, climbing groundsel herb, cordate houttuynia, cactus, sophora flavescens and other plants. Water is added in the above raw materials, and the weight/volume ratio of raw materials to water is 10-30. After that, the water extraction is conducted twice or thrice at a certain temperature for 1-3 hours each time, and obtained extracting solutions are combined to obtain the water extracts of the above raw materials. The above water extracts of the pure-natural raw materials are respectively prepared into solutions of 1g/L in scrude herbal concentration and the solutions are mixed in a precise ratio to form the pure-vegetable and pure-natural sterilization and antiviral agent. The sterilization and antiviral agent is strong in bactericidal power, free of any toxic or side effect, non-irritant, free of residues, stable, safe and efficient.
Gingival recession is defined as the migration of the marginal tissue toward the apical of the cementoenamel junction. It is one of the most common mucogingival deformities requiring surgical correction. The rationale for treating buccal recessions are mainly aesthetic concerns, and clinical situations where unfavourable contour of the gingival margin might be an obstacle for proper plaque control. Cairo et al in 2018 categorised GRs into 3 types with reference to interdental clinical attachment loss as RT1, RT2 and RT3. Mid-buccal GRs have root coverage potential through periodontal plastic surgery procedures. Coronally positioned flap is a simple and predictable treatment of gingival recession defects. It has been observed that a flap thickness of \> 0.8 mm results in a covered root surface of 100%, whereas a flap thickness of \< 0.8 mm results in partial root coverage in CAF procedure. Microneedling (MN), creates microinjuries that result in minimal superficial bleedings and create a wound-healing cascade from which various growth factors are released. MN as opposed to Connective Tissue Grafts is a non-surgical approach to increase gingival thickness, that results in significant changes in the Gingival Thickness of individuals with thin gingival phenotype.
Severe trauma with massive active blood loss, including liver and spleen rupture, arterial bleeding and pelvic fracture, will lead disability, malformation and even death. Therefore, it is very important to develop new, fast and efficient hemostatic materials. In this study, a novel Gelatin/Kaolin (GE/KA) composite sponge was developed. Meanwhile, to further investigate the effect of kaolin content on sponge properties, we prepared four types of sponges: GE/5% KA, GE/10% KA, GE/15% KA and GE/20% KA. The results of coagulation test in vitro showed that compared to the other groups, there were more activated adhered platelets and red blood cells on the surface of GE/15% KA. The results of hemostasis test in vivo showed that compared to other experimental groups, the GE/15% KA group had significantly less hemostasis time (liver hemostasis model: 69.50 ± 2.81 s; femoral artery hemostasis model: 75.17 ± 3.06 s) and bleeding volume (liver hemostasis model: 219.02 ± 10.39 mg; femoral artery hemostasis model: 948.00 ± 50.69 mg), and was similar to the commercial hemostasis material group. Additionally, the material properties of the sponge were characterized and its biocompatibility was verified as well through cell experiments and in vivo embedding experiments. All these results indicate that the optimal content of kaolin is 15%, which provides a theoretical basis for subsequent research. All in all, the novel GE/KA composite sponge prepared in this study can be used as a multifunctional hemostatic wound dressing for the treatment of complex wounds under various trauma scenes.
The invention discloses a macrolide immunosuppressant drug loaded nanomicelle. The drug loaded system adopts a suitable pharmaceutical surfactant molecule and other pharmaceutical excipients which cooperate with drugs according to a certain ratio so as to prepare stable nano-size drug loaded micelle which can disperse uniformly in water. The drug loaded micelle system has characteristics of good water-solubility, small particle size and uniform distribution. Furthermore, the drug loaded micelle has fairly good freeze-drying stability. A freeze-dried powder can redissolve to form a pharmaceutical aqueous solution with an approximate particle size compared with that before freeze drying. The nanomicelle drug loaded system provided by the invention provides a simple and effective solution to the problems of poor water-solubility and complex preparation of the macrolide medicines.
BACKGROUND: Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily affects the skin and peripheral nervous system and is caused by chromosomal abnormalities and mostly truncating variants in the NF1 gene. Ocular complications such as Lisch nodules and optic pathway gliomas (OPGs) can occur in NF1 patients. Herein, we report a novel NF1 variant in an NF1 patient with bilateral optic atrophy.
METHODS: Ophthalmological examinations and genetic analyses were performed using targeted next-generation sequencing (NGS).
RESULTS: A 14-year-old girl diagnosed with NF1 visited our hospital with decreased visual acuity (VA). The patient had no family history of NF1 or visual impairment. Brain and orbital magnetic resonance imaging revealed no remarkable findings. Ophthalmoscopy revealed temporal pallor of the optic discs, which was confirmed by optical coherence tomography findings of significant thinning of the circumpapillary retinal nerve fiber layer in both eyes. At 23 years of age, the decimal-corrected VA had deteriorated to 0.2 in the right eye and 0.1 in the left eye. Additionally, the targeted NGS panel revealed a novel heterozygous stop-gain variant (p.Tyr628Ter) in the NF1 gene; however, no pathogenic variants in OPA1 or the mitochondrial DNA were identified.
CONCLUSIONS: A patient with NF1 without OPGs developed bilateral optic atrophy and carried a novel de novo stop-gain variant of NF1. Although the relationship between NF1 variants and bilateral optic atrophy remains unclear, further investigations are required.
Anaphylaxis to CINQAIR was reported in 0.3% of asthma patients in placebo-controlled clinical studies [see Adverse Reactions (6.1)]. These events were observed during or within 20 minutes after completion of the CINQAIR infusion and reported as early as the second dose of CINQAIR. Manifestations included dyspnea, decreased oxygen saturation, wheezing, vomiting, and skin and mucosal involvement, including urticaria. In all 3 cases, CINQAIR was discontinued. 

Anaphylaxis can be life-threatening. CINQAIR should be administered by a healthcare professional prepared to manage anaphylaxis. Patients should be observed for an appropriate period of time after CINQAIR administration. If severe systemic reactions, including anaphylaxis, occur, stop administration of CINQAIR immediately and provide appropriate medical treatment. Prior to CINQAIR administration, inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care if symptoms occur. Discontinue CINQAIR use permanently if the patient experiences signs or symptoms of anaphylaxis [see Contraindications (4)].
There is an urgent need for expedited approval and access for new health technologies targeting rare and very rare diseases, some of which are associated with high unmet treatment needs. Once a new technology achieves regulatory approval, the technology needs to be assessed by health technology assessment (HTA) bodies to inform coverage and reimbursement decisions. This assessment quantitatively examines the clinical effectiveness, safety and/or economic impact of the new technology relative to standard of care (SoC) in a specific market. However, in rare and very rare diseases, the patient populations are small and there is often no established treatment pathway available to define 'SoC'. In these situations, several challenges arise to assess the added benefit of a new technology - both clinically and economically - due to lack of established SoC to guide an appropriate comparator selection. These challenges include: How should 'SoC' be defined and characterized in HTA submissions for new technologies aiming to establish new treatment standards? What is usual care without an established clinical pathway? How should the evidence for the comparator 'SoC' (i.e., usual care) arm be collected in situations with low patient representation and, sometimes, limited disease-specific clinical knowledge in certain geographies? This commentary outlines the evidence generation challenges in designing clinical comparative effectiveness for a new technology when there is a lack of established SoC. The commentary also proposes considerations to facilitate the reliable integration of real-world evidence into HTA and decision-making based on the collective experience of the authors.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical and cosmetic industry, in particular to otologic composition for dissolving, destruction and removal of earwax from ear canal. Otologic composition for dissolving, destruction and removal of earwax from ear canal, including extract of lapacho bark. Method of dissolving, destruction and removal of earwax in ear canal by means of otologic composition. ^ EFFECT: composition efficiently dissolves, destroys and removes earwax in ear canal. ^ 7 cl, 2 ex
The invention pertains to compositions and methods to treat the adverse effects of mustard chemicals and other toxic compounds, such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concentrations of such a vesciant, compositions comprising (a) a matrix metalloproteinase inhibitor, MMPI, and (b) a protease inhibitor, PI, such as a serine protease inhibitor, SPI, a significant reduction on morbidity is achieved with increased concentrations of the compositions of this invention, as compared with an MMPI inhibitor alone or vehicle alone. Furthermore, compositions comprising the MMPI, the SPI, and in addition, an anti-inflammatory compound, in a vehicle appropriate to the type of tissue damage and inflammation, as compared with anti-inflammatory composition alone. Chemicals having more than one property, such as MMPI and AIA properties, are also disclosed. Certain combinations disclosed are applied to treat injuries are also disclosed. Certain combinations disclosed are applied to treat injuries are also disclosed. Certain combinations disclosed are applied to treat injuries due to acids and bases.
Gastric cancer (GC) constitutes substantial cancer mortality worldwide. Several cancer types aberrantly express bone marrow stromal cell antigen 2 (BST2), yet its functional and underlying mechanisms in GC progression remain unknown. In our study, RNA sequencing data revealed that BST2 was transcriptionally activated by homeobox D9 (HOXD9). BST2 was significantly upregulated in GC tissues and promoted epithelial-mesenchymal transition and metastasis of GC. BST2 knockdown reversed HOXD9's oncogenic effect on GC metastasis. Moreover, BST2 messenger RNA stability could be enhanced by poly(A) binding protein cytoplasmic 1 (PABPC1) through the interaction between BST2 3'-UTR and PABPC1 in GC cells. PABPC1 promoted GC metastasis, which BST2 silencing attenuated in vitro and in vivo. In addition, positive correlations among HOXD9, BST2, and PABPC1 were established in clinical samples. Taken together, increased expression of BST2 induced by HOXD9 synergizing with PABPC1 promoted GC cell migration and invasion capacity.
Adults will receive bivalent OPV (types 1 and 3) on Day 1 and Day 29. Each dose (2 drops = 0.1 mL) contains \>10\^6.0 infective units of type 1 and \>10\^5.8 of type 3.
FIELD: apitherapeutic preparations, prophylaxis. SUBSTANCE: the cream in question could be used to prevent cardiovascular diseases, osteochondrosis of spinal column cervical department, disorders of brain circulation, risk of vegetovascular dystonia, neuritis of auditory, trigeminal and facial nerves. Antisclerotic cream based upon bee honey additionally contains propolis wax, bee poison, flower pollen extract tincture, thick propolis extract, lanolin, bee pellitory tincture and fatty foundation as a vegetable oil, and water. Moreover, the components should be taken at the following ratio, weight%: wax 5- 6, bee honey 20-24, bee poison 0.0001-0.0002, flower pollen extract 0.4, thick propolis 3.5, lanolin 12, bee pellitory tincture 8, fatty foundation 45-50, water - the rest. The cream is very simple to be manufactured and requires no special techniques for its application. EFFECT: higher efficiency of prophylaxis. 1 cl, 1 tbl
Regardless of the indication, the starting dose in patients with moderate hepatic impairment should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild hepatic insufficiency do not require dosage reductions. The use of pilocarpine in patients with severe hepatic insufficiency is not recommended. If needed, refer to the Hepatic Insufficiency subsection of the Precautions section of this label for definitions of mild, moderate and severe hepatic impairment.  
  
Head & Neck Cancer Patients: The recommended initial dose of SALAGEN® Tablets is 5 mg taken three times a day. Dosage should be titrated according to therapeutic response and tolerance. The usual dosage range is up to 15-30 mg per day. (Not to exceed 10 mg per dose.) Although early improvement may be realized, at least 12 weeks of uninterrupted therapy with SALAGEN® Tablets may be necessary to assess whether a beneficial response will be achieved. The incidence of the most common adverse events increases with dose. The lowest dose that is tolerated and effective should be used for maintenance.  
  
Sjogren's Syndrome Patients: The recommended dose of SALAGEN® Tablets is 5 mg taken four times a day. Efficacy was established by 6 weeks of use.